Chemours (NYSE:CC) Now Covered by Truist Financial

Equities researchers at Truist Financial assumed coverage on shares of Chemours (NYSE:CC) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $27.00 price target on the specialty chemicals company’s stock. Truist Financial’s target price points to a potential upside of 41.42% from the company’s current price.

CC has been the topic of a number of other research reports. Mizuho cut their price target on shares of Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Barclays increased their price objective on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. The Goldman Sachs Group reduced their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Royal Bank of Canada restated an “outperform” rating and issued a $25.00 price objective on shares of Chemours in a research note on Thursday, December 12th. Finally, Morgan Stanley lowered their target price on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $24.11.

Chemours Stock Down 2.9 %

Shares of NYSE:CC opened at $19.09 on Tuesday. Chemours has a 52 week low of $15.10 and a 52 week high of $31.76. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The company has a market cap of $2.85 billion, a PE ratio of 38.18 and a beta of 1.83. The firm has a 50 day simple moving average of $19.18 and a 200 day simple moving average of $19.59.

Chemours (NYSE:CC) last released its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 EPS. As a group, research analysts expect that Chemours will post 1.19 earnings per share for the current year.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Institutional Investors Weigh In On Chemours

A number of hedge funds and other institutional investors have recently made changes to their positions in CC. Matrix Trust Co acquired a new stake in shares of Chemours in the third quarter valued at about $25,000. Blue Trust Inc. grew its stake in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock valued at $26,000 after buying an additional 731 shares in the last quarter. GAMMA Investing LLC increased its holdings in Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 765 shares during the last quarter. Truvestments Capital LLC acquired a new stake in Chemours in the third quarter valued at $35,000. Finally, Brooklyn Investment Group bought a new stake in shares of Chemours in the 3rd quarter valued at about $37,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.